-
Lancet oncol: Liu-Inspired Team - Phase III Clinical Trials - AML After Transplantation, Sorafini is used to maintain the efficacy and tolerability of the treatment.
Time of Update: 2020-09-01
The trial recruited acute myeloid leukemia patients aged 18-60 with FRT3-ITD who were planning an allogygenic hematopoietic stem cell transplant and required ECOG performance of 0-2 points, full remission before and after the transplant, and hematological recovery within 60 days of transplantation.
-
J Thromb Haemost: Retinal vascular blockage of adult hereditary or obtainable thrombosis tendencies.
Time of Update: 2020-09-01
all adult patients with RAO or RVO reported coagulation factor V Leiden (FVL) and coagulant enzymatic (F-II) G20210A mutations, MTHFR C677T and PAI 4G polymorphism, anticoagulant Studies of enzyme III (AT-III), protein C (PC) and protein S (PS) inactivity, hyperisocysteineemia, and antiphospholipid (APL) antibody prevalence were included in the analysis, and the combined prevalence and 95% confidence interval (CI) were calculated.
-
Inventory: A selection of Blood studies dated August 13, 2020.
Time of Update: 2020-09-01
Most bleeding abnormalities are associated with coagulation factor dysfunction, and researchers recently established a cell-based analysis method to determine drugs that may have off-target effects that affect active vitamin K dependence (VKD) coagulation factor biosynthesis.
-
Blood: Myeloid ancestors from bone marrow sources are carriers of mutations driven by longeghans cell tissue cell growth.
Time of Update: 2020-09-01
In-body, CD34-c-Kit-FLT3-plus precellular cells from the external blood sources of high- and low-risk LCH patients can produce DC and LC-like cells, but their driving mutations are not easily detected and may be due to the low percentage of the mutation's ancestor cells.
-
Blood: Hemococotin deficiency promotes acute kidney damage in patients with sickle cell disease!
Time of Update: 2020-09-01
Center point: In sickle cell disease (SCD), the ratio of plasma alpha-1 microglobulin to hemacoglobin concentration is associated with AKI biomarkers.
: Acute kidney injury (AKI) is one of the main clinical manifestations of sickle cell disease (SCD).
-
NEJM: Vinetola combined with aza cytoside to treat acute myeloid leukemia in old age.
Time of Update: 2020-09-01
studies have concluded that Vinetola combined azadenosine can effectively prolong the survival of elderly patients with acute myeloid leukemia aged 75 years and older.
-
JAMA: Red blood cell infusion and risk of poor prognostication in very low-weight newborns.
Time of Update: 2020-09-01
study found that for babies born weighing less than 1,000 grams, not limiting red blood cell infusions did not reduce the risk of death or disability at 24 months.
-
Blood: Hereditary alpha-trypsinemia is an effective genetic biomarker of hypertrophic cell hypertrophic disorder.
Time of Update: 2020-09-01
assessed the TPSAB1 embryonic copy number variation in 180 hypertrophic cell hypertrophic patients, 180 gender-matched control individuals, 720 other myelin tumor patients, and an additional 61 hypertrophic cell hypertrophic patients in a separate validation queue with PCR.
-
Blood: Emicizumab treats obtained haemophilia A.
Time of Update: 2020-09-01
bypass therapy, human or pig FVIII is currently the standard treatment for AHA hemolysis.
after the 31st day (15-79 days), the emicizumab was deactivation, with a median injection of 5 times (range 3-9), and after 115 days (67-185 days), FVIII (bovine reagent) activity exceeded 50%, suggesting complete remission.
-
Blood: Avelumab treats recurrent/incurable NK/T cell lymphoma.
Time of Update: 2020-09-01
study (NCT03439501) was designed to evaluate the efficacy and safety of avelumab for recurrent/incurable out-of-knot natural killers (NK)/T-cell lymphoma (ENKTL).
therefore, tumor tissue in all patients receiving CR had high expression of PD-L1, and tumor substations based on PD-L1 expression were associated with therapeutic responses.
-
Lancet haematol: Clinical characteristics and adverse prognostic factors in patients with blood malignancies infected with COVID-19.
Time of Update: 2020-09-01
goal of the Italian COVID-19 Hematology Alliance is to collect data on adult patients with blood malignancies that require hospitalization due to COVID-19.
the study cohort had a standardized mortality rate of 41.3 (38.1-44.9) compared to patients with non-COVID-19 infected blood malignancies.
-
NEJM: Venetoclax Treatment of Acute Myeloid Leukemia (AML), Phase III Clinically Positive Results.
Time of Update: 2020-09-01
AbbVie announced today that the results of Phase III clinical trials (VIALE-A) published in the New England Journal of Medicine (NEJM) assessed the effectiveness and safety of veetoclax in the treatment of primary AML patients, and showed that venetoclax combined azacsides extended overall survival (OS) compared to placebo combined azacine.
-
Same case, but with different results, who is changing?
Time of Update: 2020-09-01
For example, for a clinical laboratory like our general staff rotating night shift, we are most afraid of being alone on the night shift encountered is not the difficult problem of this professional g
-
Blood: Prostatin E2 restores the sensitivity of leukemia cells to glucoscosteroids.
Time of Update: 2020-09-01
In addition, the researchers found that prostatin E recepposer 4 was expressed in T-ALL samples and demonstrated that prostin E2 (PGE2) increases in-cell cAMP, enhances GC-induced gene expression, and makes T-ALL samples sensitive to desermison.
-
The cause of anemia is too complex, these 3 tests are easy to identify!
Time of Update: 2020-09-01
And, in other anemia diseases that are easily confused with iron deficiency anemia or giant larvae anemia (e.g. iron granulocytic anemia, thalassemia, bone marrow growth abnormal syndrome, etc.), the three anemias are also of great significance for differential diagnosis.
-
Blood: Targeting VWF prevents traumatic brain injury-induced clotting.
Time of Update: 2020-09-01
in the study, the researchers reported findings that validated the hypothesis that "the von Willebrand factor (VWF) released during acute TBI is inherently highly adhesionable because its plateles combined with the A1 domain have been exposed, promoting TBI-induced vascular leakage and expendable clotting." this highly adhesion VWF can be selectively blocked by VWF A2 domain proteins to prevent TBI-ICs, improve nerve function, and minimize the risk of bleeding.
-
Blood: CBRN multiple mutations associated with multiple myeloma and drug resistance to lysamine or pomadamine.
Time of Update: 2020-09-01
it is understood that this study is the first comprehensive analysis of CBRN variation in patients with myeloma who are progressing in treatment, which can help guide patients to choose the sequence therapy of CRBN-targeted drugs.
-
Blood: About half of ITP patients may have hidden brain haemorrhage!
Time of Update: 2020-08-23
researchers used susceptible weighted MRI (SWI) to detect cerebral microbleeding (CMB) as a sign of hidden bleeding.
hidden cerebral microbleeding is common in moderate to severe ITP patients.
correlation, neither low plateboard counts nor bleeding scores can predict CMB.
-
Blood: SLFN11 promotes DNA replication fork degradation, which mediates the occurrence of van Nico anemia.
Time of Update: 2020-08-23
in this study, Okamoto, among others, reported that SLFN11, a PD20 cell line that knocks out FANCD2 defects from FA patient sources, improved cell survival under ITL inducing agent therapy.
, the researchers found that SLFN11 promoted widespread degradation of replication forks in FANCD2-/-cells.
-
The first antibody drug to target BCMA, Blenrep, was approved by the FDA for accelerated treatment of recurrent or recurrent multiple myeloma.
Time of Update: 2020-08-22
GlaxoSmithKline announced that the FDA has accelerated approval of Belantamab mafodotin-blmf for the treatment of adult patients with recurrent or recurrent multiple myeloma who have received at least four previous treatments, including anti-CD38 monoclonal antibodies, protease inhibitors, and immunomodants.
